et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naive EGFR mutant non-small cell lung cancer (NSCLC) and potential biomarkers for response. ASCO Annual Meeting - Bauml, JM (2021)
Abstract 9006